These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17085048)
1. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation. Liu T; Xu Z; He Q; Chen Y; Yang B; Hu Y Bioorg Med Chem Lett; 2007 Jan; 17(1):278-81. PubMed ID: 17085048 [TBL] [Abstract][Full Text] [Related]
2. Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: synthesis, SAR analysis, and biological activity. Zhang S; Ma J; Bao Y; Yang P; Zou L; Li K; Sun X Bioorg Med Chem; 2008 Aug; 16(15):7128-33. PubMed ID: 18639462 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents. Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631 [TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755 [TBL] [Abstract][Full Text] [Related]
5. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100 [TBL] [Abstract][Full Text] [Related]
6. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition. Andreani A; Cavalli A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Recanatini M; Garnier M; Meijer L Anticancer Drug Des; 2000 Dec; 15(6):447-52. PubMed ID: 11716438 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors. Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Chen S; Chen L; Le NT; Zhao C; Sidduri A; Lou JP; Michoud C; Portland L; Jackson N; Liu JJ; Konzelmann F; Chi F; Tovar C; Xiang Q; Chen Y; Wen Y; Vassilev LT Bioorg Med Chem Lett; 2007 Apr; 17(8):2134-8. PubMed ID: 17303421 [TBL] [Abstract][Full Text] [Related]
10. Structure-aided optimization of kinase inhibitors derived from alsterpaullone. Kunick C; Zeng Z; Gussio R; Zaharevitz D; Leost M; Totzke F; Schächtele C; Kubbutat MH; Meijer L; Lemcke T Chembiochem; 2005 Mar; 6(3):541-9. PubMed ID: 15696597 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors. Lee J; Kim KH; Jeong S Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). Huang S; Li R; Connolly PJ; Emanuel S; Fuentes-Pesquera A; Adams M; Gruninger RH; Seraj J; Middleton SA; Davis JM; Moffat DF Bioorg Med Chem Lett; 2007 Apr; 17(8):2179-83. PubMed ID: 17317182 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors. Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039 [TBL] [Abstract][Full Text] [Related]
15. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases. Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors. Mou J; Qiu S; Chen D; Deng Y; Tekleab T Chem Biol Drug Des; 2021 Oct; 98(4):639-654. PubMed ID: 34233076 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. Akue-Gedu R; Debiton E; Ferandin Y; Meijer L; Prudhomme M; Anizon F; Moreau P Bioorg Med Chem; 2009 Jul; 17(13):4420-4. PubMed ID: 19477650 [TBL] [Abstract][Full Text] [Related]
18. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609 [TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403 [TBL] [Abstract][Full Text] [Related]
20. Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors. Verma S; Nagarathnam D; Shao J; Zhang L; Zhao J; Wang Y; Li T; Mull E; Enyedy I; Wang C; Zhu Q; Altieri M; Jordan J; Dang TT; Reddy S Bioorg Med Chem Lett; 2005 Apr; 15(8):1973-7. PubMed ID: 15808450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]